Welcome to our dedicated page for LeMaitre Vascular news (Ticker: $LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LeMaitre Vascular's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LeMaitre Vascular's position in the market.
LeMaitre, a provider of vascular devices, implants, and services, reported strong Q1 2024 financial results with sales up 14%, operating income up 51%, and net income up 64%. The company announced a $0.16/share quarterly dividend and provided guidance for Q2 2024 and full-year 2024, expecting double-digit growth in sales, operating income, and EPS. The gross margin improved to 68.6%, driven by increased selling prices and manufacturing efficiencies. The company's CEO expects a 22% operating margin for 2024.